BR112021004052A2 - amidas de dimetil-amino azetidina como inibidores de jak - Google Patents

Info

Publication number

BR112021004052A2

BR112021004052A2 BR112021004052-8A BR112021004052A BR112021004052A2 BR 112021004052 A2 BR112021004052 A2 BR 112021004052A2 BR 112021004052 A BR112021004052 A BR 112021004052A BR 112021004052 A2 BR112021004052 A2 BR 112021004052A2

Authority

BR

Brazil

Prior art keywords

compound

disease

lung

pharmaceutically acceptable

transplant rejection

Prior art date

2018-09-04

Links

• Espacenet
• Global Dossier
• Discuss

• 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract description 16
• -1 dimethyl-amino azetidine amides Chemical class 0.000 title description 45
• 150000001875 compounds Chemical class 0.000 claims abstract description 274
• 150000003839 salts Chemical class 0.000 claims abstract description 61
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 49
• 238000000034 method Methods 0.000 claims abstract description 45
• 208000023504 respiratory system disease Diseases 0.000 claims abstract description 27
• 208000006673 asthma Diseases 0.000 claims description 43
• 206010035664 Pneumonia Diseases 0.000 claims description 32
• 206010051604 Lung transplant rejection Diseases 0.000 claims description 30
• 241000124008 Mammalia Species 0.000 claims description 26
• 239000003814 drug Substances 0.000 claims description 26
• 206010035742 Pneumonitis Diseases 0.000 claims description 24
• 238000011282 treatment Methods 0.000 claims description 22
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 21
• 208000024908 graft versus host disease Diseases 0.000 claims description 21
• 208000034706 Graft dysfunction Diseases 0.000 claims description 20
• 230000001684 chronic effect Effects 0.000 claims description 20
• 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 17
• 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 17
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 17
• 230000002685 pulmonary effect Effects 0.000 claims description 17
• 230000001154 acute effect Effects 0.000 claims description 16
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 12
• 206010067472 Organising pneumonia Diseases 0.000 claims description 12
• 208000019693 Lung disease Diseases 0.000 claims description 11
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 10
• 239000003937 drug carrier Substances 0.000 claims description 10
• 230000002327 eosinophilic effect Effects 0.000 claims description 10
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 9
• 206010006448 Bronchiolitis Diseases 0.000 claims description 8
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 8
• 208000004530 Primary Graft Dysfunction Diseases 0.000 claims description 8
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 8
• 206010014561 Emphysema Diseases 0.000 claims description 7
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 7
• 206010069351 acute lung injury Diseases 0.000 claims description 7
• 206010006451 bronchitis Diseases 0.000 claims description 7
• 201000009805 cryptogenic organizing pneumonia Diseases 0.000 claims description 7
• 229940079593 drug Drugs 0.000 claims description 7
• 230000001900 immune effect Effects 0.000 claims description 7
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 7
• 230000000527 lymphocytic effect Effects 0.000 claims description 7
• 230000003448 neutrophilic effect Effects 0.000 claims description 7
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 6
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
• 201000009267 bronchiectasis Diseases 0.000 claims description 6
• 230000002538 fungal effect Effects 0.000 claims description 6
• 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims description 5
• 206010010187 Complications of transplanted lung Diseases 0.000 claims description 5
• 208000027004 Eosinophilic disease Diseases 0.000 claims description 5
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 5
• 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims description 5
• 208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 claims description 5
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
• 238000004519 manufacturing process Methods 0.000 claims description 5
• 208000011580 syndromic disease Diseases 0.000 claims description 5
• 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims description 4
• 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 4
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 4
• 201000009324 Loeffler syndrome Diseases 0.000 claims description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
• 206010061201 Helminthic infection Diseases 0.000 claims 3
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
• 108091000080 Phosphotransferase Proteins 0.000 abstract description 7
• 102000020233 phosphotransferase Human genes 0.000 abstract description 7
• 239000000243 solution Substances 0.000 description 92
• 210000004027 cell Anatomy 0.000 description 84
• 239000011541 reaction mixture Substances 0.000 description 80
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 73
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
• 210000004072 lung Anatomy 0.000 description 64
• 238000003556 assay Methods 0.000 description 62
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
• 238000012360 testing method Methods 0.000 description 55
• 238000006243 chemical reaction Methods 0.000 description 52
• 239000003112 inhibitor Substances 0.000 description 50
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 47
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 47
• 230000005764 inhibitory process Effects 0.000 description 46
• 238000005516 engineering process Methods 0.000 description 45
• 239000000203 mixture Substances 0.000 description 42
• 102000004127 Cytokines Human genes 0.000 description 37
• 108090000695 Cytokines Proteins 0.000 description 37
• 230000036515 potency Effects 0.000 description 37
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
• 239000002253 acid Substances 0.000 description 34
• 239000012043 crude product Substances 0.000 description 34
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 32
• 210000001744 T-lymphocyte Anatomy 0.000 description 32
• 235000019439 ethyl acetate Nutrition 0.000 description 32
• 239000000872 buffer Substances 0.000 description 28
• 239000000047 product Substances 0.000 description 27
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 26
• 229910002091 carbon monoxide Inorganic materials 0.000 description 26
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 26
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 25
• 239000007787 solid Substances 0.000 description 25
• 239000003981 vehicle Substances 0.000 description 24
• 108010002350 Interleukin-2 Proteins 0.000 description 22
• 102000000588 Interleukin-2 Human genes 0.000 description 22
• 210000004369 blood Anatomy 0.000 description 22
• 239000008280 blood Substances 0.000 description 22
• 230000002829 reductive effect Effects 0.000 description 22
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
• 239000005557 antagonist Substances 0.000 description 21
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 21
• 238000005160 1H NMR spectroscopy Methods 0.000 description 20
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
• 108090001005 Interleukin-6 Proteins 0.000 description 19
• 210000001519 tissue Anatomy 0.000 description 19
• 102000004889 Interleukin-6 Human genes 0.000 description 18
• 201000010099 disease Diseases 0.000 description 18
• 229940100601 interleukin-6 Drugs 0.000 description 18
• 230000026731 phosphorylation Effects 0.000 description 18
• 238000006366 phosphorylation reaction Methods 0.000 description 18
• 108090000176 Interleukin-13 Proteins 0.000 description 17
• 102000003816 Interleukin-13 Human genes 0.000 description 17
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
• 238000002953 preparative HPLC Methods 0.000 description 17
• 206010061218 Inflammation Diseases 0.000 description 16
• 238000004458 analytical method Methods 0.000 description 16
• 230000004054 inflammatory process Effects 0.000 description 16
• 230000002401 inhibitory effect Effects 0.000 description 16
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
• 239000000843 powder Substances 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 16
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
• 239000003795 chemical substances by application Substances 0.000 description 15
• 229940125904 compound 1 Drugs 0.000 description 15
• 239000012091 fetal bovine serum Substances 0.000 description 15
• 239000000543 intermediate Substances 0.000 description 15
• 239000003446 ligand Substances 0.000 description 15
• 239000012074 organic phase Substances 0.000 description 15
• 229940124597 therapeutic agent Drugs 0.000 description 15
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
• 238000010790 dilution Methods 0.000 description 14
• 239000012895 dilution Substances 0.000 description 14
• 238000004809 thin layer chromatography Methods 0.000 description 14
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
• 239000007821 HATU Substances 0.000 description 13
• 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 13
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 13
• 238000004440 column chromatography Methods 0.000 description 13
• 230000000694 effects Effects 0.000 description 13
• 230000028327 secretion Effects 0.000 description 13
• 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 13
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 12
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
• HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 12
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 239000007995 HEPES buffer Substances 0.000 description 12
• 241001465754 Metazoa Species 0.000 description 12
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 12
• 239000012267 brine Substances 0.000 description 12
• 239000006227 byproduct Substances 0.000 description 12
• 230000001413 cellular effect Effects 0.000 description 12
• 210000003979 eosinophil Anatomy 0.000 description 12
• 230000004044 response Effects 0.000 description 12
• 239000000741 silica gel Substances 0.000 description 12
• 229910002027 silica gel Inorganic materials 0.000 description 12
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
• 230000000638 stimulation Effects 0.000 description 12
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 11
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 11
• 108010002616 Interleukin-5 Proteins 0.000 description 11
• 102100039897 Interleukin-5 Human genes 0.000 description 11
• 238000012544 monitoring process Methods 0.000 description 11
• 239000000546 pharmaceutical excipient Substances 0.000 description 11
• 229910052938 sodium sulfate Inorganic materials 0.000 description 11
• 235000011152 sodium sulphate Nutrition 0.000 description 11
• 230000009885 systemic effect Effects 0.000 description 11
• 239000012114 Alexa Fluor 647 Substances 0.000 description 10
• 102000004388 Interleukin-4 Human genes 0.000 description 10
• 108090000978 Interleukin-4 Proteins 0.000 description 10
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 10
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
• 206010009887 colitis Diseases 0.000 description 10
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
• 229940028885 interleukin-4 Drugs 0.000 description 10
• 239000007788 liquid Substances 0.000 description 10
• 229940071648 metered dose inhaler Drugs 0.000 description 10
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
• 102100023698 C-C motif chemokine 17 Human genes 0.000 description 9
• 108010082169 Chemokine CCL17 Proteins 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 230000001419 dependent effect Effects 0.000 description 9
• 239000003480 eluent Substances 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• 229910052757 nitrogen Inorganic materials 0.000 description 9
• 230000000770 proinflammatory effect Effects 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• GLWKVDXAQHCAIO-REYDXQAISA-N 3-[(2z,5z)-2-[[3-(2-carboxyethyl)-5-[[(2r)-4-ethenyl-3-methyl-5-oxo-1,2-dihydropyrrol-2-yl]methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[[(3z,4r)-3-ethylidene-4-methyl-5-oxopyrrol-2-yl]methylidene]-4-methylpyrrol-3-yl]propanoic acid Chemical compound C\C=C1\[C@@H](C)C(=O)N=C1\C=C(/N\1)C(C)=C(CCC(O)=O)C/1=C/C1=C(CCC(O)=O)C(C)=C(C[C@@H]2C(=C(C=C)C(=O)N2)C)N1 GLWKVDXAQHCAIO-REYDXQAISA-N 0.000 description 8
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 8
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 8
• 108010066979 Interleukin-27 Proteins 0.000 description 8
• IGJXAXFFKKRFKU-UHFFFAOYSA-N Phycoerythrobilin Natural products CC=C/1C(NC(C1C)=O)=Cc2[nH]c(C=C3/N=C(CC4NC(=O)C(=C4C)C=C)C(=C3CCC(=O)O)C)c(CCC(=O)O)c2C IGJXAXFFKKRFKU-UHFFFAOYSA-N 0.000 description 8
• 239000013543 active substance Substances 0.000 description 8
• 238000004128 high performance liquid chromatography Methods 0.000 description 8
• 210000001616 monocyte Anatomy 0.000 description 8
• 239000006199 nebulizer Substances 0.000 description 8
• 108010012759 phycoerythrobilin Proteins 0.000 description 8
• 229940075993 receptor modulator Drugs 0.000 description 8
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 7
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 7
• 108060003951 Immunoglobulin Proteins 0.000 description 7
• 108010074328 Interferon-gamma Proteins 0.000 description 7
• 102000008070 Interferon-gamma Human genes 0.000 description 7
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 239000000556 agonist Substances 0.000 description 7
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 7
• 125000004432 carbon atom Chemical group C* 0.000 description 7
• 229940112141 dry powder inhaler Drugs 0.000 description 7
• WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 7
• 125000000623 heterocyclic group Chemical group 0.000 description 7
• 239000001257 hydrogen Substances 0.000 description 7
• 229910052739 hydrogen Inorganic materials 0.000 description 7
• 102000018358 immunoglobulin Human genes 0.000 description 7
• 239000008101 lactose Substances 0.000 description 7
• 239000010410 layer Substances 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 230000003389 potentiating effect Effects 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
• 239000006228 supernatant Substances 0.000 description 7
• 238000002054 transplantation Methods 0.000 description 7
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
• GGTNZZHNKRQNLH-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine-6-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1N=CN2 GGTNZZHNKRQNLH-UHFFFAOYSA-N 0.000 description 6
• 241000223600 Alternaria Species 0.000 description 6
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 6
• 229920001917 Ficoll Polymers 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 6
• 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 6
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 6
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 210000004443 dendritic cell Anatomy 0.000 description 6
• 238000000605 extraction Methods 0.000 description 6
• 239000000706 filtrate Substances 0.000 description 6
• 229960000289 fluticasone propionate Drugs 0.000 description 6
• 229960002462 glycopyrronium bromide Drugs 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 230000002757 inflammatory effect Effects 0.000 description 6
• 229960003130 interferon gamma Drugs 0.000 description 6
• 239000003380 propellant Substances 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 229940044551 receptor antagonist Drugs 0.000 description 6
• 239000002464 receptor antagonist Substances 0.000 description 6
• 229960002052 salbutamol Drugs 0.000 description 6
• 201000000306 sarcoidosis Diseases 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
• PGMBVOVVYOIMBB-UHFFFAOYSA-N 1-ethyl-3-phenylmethoxybenzene Chemical compound CCC1=CC=CC(OCC=2C=CC=CC=2)=C1 PGMBVOVVYOIMBB-UHFFFAOYSA-N 0.000 description 5
• SVPDDTOIPKRVQR-UHFFFAOYSA-N 2-(2-ethyl-4-phenylmethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1)B1OC(C(O1)(C)C)(C)C)CC SVPDDTOIPKRVQR-UHFFFAOYSA-N 0.000 description 5
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
• 102000019034 Chemokines Human genes 0.000 description 5
• 108010012236 Chemokines Proteins 0.000 description 5
• 206010012438 Dermatitis atopic Diseases 0.000 description 5
• 238000002965 ELISA Methods 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 108010065805 Interleukin-12 Proteins 0.000 description 5
• 102000013462 Interleukin-12 Human genes 0.000 description 5
• 230000004163 JAK-STAT signaling pathway Effects 0.000 description 5
• 206010025323 Lymphomas Diseases 0.000 description 5
• 101710199268 Periostin Proteins 0.000 description 5
• 102100037765 Periostin Human genes 0.000 description 5
• 108010011005 STAT6 Transcription Factor Proteins 0.000 description 5
• 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 5
• 125000000217 alkyl group Chemical group 0.000 description 5
• 125000004429 atom Chemical group 0.000 description 5
• 201000008937 atopic dermatitis Diseases 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 235000019441 ethanol Nutrition 0.000 description 5
• 208000030533 eye disease Diseases 0.000 description 5
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
• 235000019253 formic acid Nutrition 0.000 description 5
• BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 5
• 229960002848 formoterol Drugs 0.000 description 5
• 229940117681 interleukin-12 Drugs 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• 230000014759 maintenance of location Effects 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 230000004060 metabolic process Effects 0.000 description 5
• 239000003921 oil Substances 0.000 description 5
• 235000019198 oils Nutrition 0.000 description 5
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
• 229960005018 salmeterol xinafoate Drugs 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 239000002002 slurry Substances 0.000 description 5
• OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 4
• 206010002091 Anaesthesia Diseases 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
• 102100040019 Interferon alpha-1/13 Human genes 0.000 description 4
• 102000015696 Interleukins Human genes 0.000 description 4
• 108010063738 Interleukins Proteins 0.000 description 4
• 208000029523 Interstitial Lung disease Diseases 0.000 description 4
• 102000042838 JAK family Human genes 0.000 description 4
• 108091082332 JAK family Proteins 0.000 description 4
• 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 4
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
• 238000005481 NMR spectroscopy Methods 0.000 description 4
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 4
• 206010042971 T-cell lymphoma Diseases 0.000 description 4
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• 230000037005 anaesthesia Effects 0.000 description 4
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
• 229910052799 carbon Inorganic materials 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 238000003818 flash chromatography Methods 0.000 description 4
• 238000000684 flow cytometry Methods 0.000 description 4
• 229960000193 formoterol fumarate Drugs 0.000 description 4
• 150000005828 hydrofluoroalkanes Chemical class 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 229940047122 interleukins Drugs 0.000 description 4
• 238000004949 mass spectrometry Methods 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
• 101150086837 pic gene Proteins 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 238000011084 recovery Methods 0.000 description 4
• 210000002345 respiratory system Anatomy 0.000 description 4
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
• 229960000215 ruxolitinib Drugs 0.000 description 4
• HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 4
• 229960004017 salmeterol Drugs 0.000 description 4
• 239000012279 sodium borohydride Substances 0.000 description 4
• 229910000033 sodium borohydride Inorganic materials 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 230000002269 spontaneous effect Effects 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• CCGHCCTXMYYHQC-NSHDSACASA-N (6S)-3,5-bis[(2-methylpropan-2-yl)oxycarbonyl]-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1C=NC2=C1CN([C@@H](C2)C(=O)O)C(=O)OC(C)(C)C CCGHCCTXMYYHQC-NSHDSACASA-N 0.000 description 3
• LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 3
• YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 3
• HMNKTRSOROOSPP-UHFFFAOYSA-N 3-Ethylphenol Chemical compound CCC1=CC=CC(O)=C1 HMNKTRSOROOSPP-UHFFFAOYSA-N 0.000 description 3
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
• YEJGHOJVLOIPLC-INIZCTEOSA-N 6-O-benzyl 5-O-tert-butyl (6S)-3,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5,6-dicarboxylate Chemical compound N1=CNC=2CN([C@@H](CC=21)C(=O)OCC1=CC=CC=C1)C(=O)OC(C)(C)C YEJGHOJVLOIPLC-INIZCTEOSA-N 0.000 description 3
• KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• 206010012688 Diabetic retinal oedema Diseases 0.000 description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 description 3
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• 102000013264 Interleukin-23 Human genes 0.000 description 3
• 108010065637 Interleukin-23 Proteins 0.000 description 3
• 229930195725 Mannitol Natural products 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• 206010034277 Pemphigoid Diseases 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
• 208000003251 Pruritus Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 108010029477 STAT5 Transcription Factor Proteins 0.000 description 3
• 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 230000006044 T cell activation Effects 0.000 description 3
• 108010010057 TYK2 Kinase Proteins 0.000 description 3
• 206010052779 Transplant rejections Diseases 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 3
• 229940127174 UCHT1 Drugs 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• 206010046851 Uveitis Diseases 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 229950000210 beclometasone dipropionate Drugs 0.000 description 3
• NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 3
• 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 3
• 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 3
• 230000002051 biphasic effect Effects 0.000 description 3
• 229910000085 borane Inorganic materials 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 150000001768 cations Chemical class 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 102000003675 cytokine receptors Human genes 0.000 description 3
• 108010057085 cytokine receptors Proteins 0.000 description 3
• 201000011190 diabetic macular edema Diseases 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 229960002714 fluticasone Drugs 0.000 description 3
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 239000005457 ice water Substances 0.000 description 3
• 238000000099 in vitro assay Methods 0.000 description 3
• 229960004078 indacaterol Drugs 0.000 description 3
• QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 229940043355 kinase inhibitor Drugs 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 208000002780 macular degeneration Diseases 0.000 description 3
• 238000007726 management method Methods 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 201000005962 mycosis fungoides Diseases 0.000 description 3
• ZUGCXQDQYRDQTR-UHFFFAOYSA-N n,n,3-trimethylazetidin-3-amine Chemical compound CN(C)C1(C)CNC1 ZUGCXQDQYRDQTR-UHFFFAOYSA-N 0.000 description 3
• MKRHDBKTGMBWHU-UHFFFAOYSA-N n,n,3-trimethylazetidin-3-amine;hydrochloride Chemical compound Cl.CN(C)C1(C)CNC1 MKRHDBKTGMBWHU-UHFFFAOYSA-N 0.000 description 3
• IRQWCOFOSMREBQ-UHFFFAOYSA-N n,n-dimethylazetidin-3-amine Chemical compound CN(C)C1CNC1 IRQWCOFOSMREBQ-UHFFFAOYSA-N 0.000 description 3
• BMUIAEREBKVJQG-UHFFFAOYSA-N n,n-dimethylazetidin-3-amine;hydrochloride Chemical compound Cl.CN(C)C1CNC1 BMUIAEREBKVJQG-UHFFFAOYSA-N 0.000 description 3
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
• UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
• VBKNTGMWIPUCRF-UHFFFAOYSA-M potassium;fluoride;hydrofluoride Chemical compound F.[F-].[K+] VBKNTGMWIPUCRF-UHFFFAOYSA-M 0.000 description 3
• 229960004583 pranlukast Drugs 0.000 description 3
• UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 230000019635 sulfation Effects 0.000 description 3
• 238000005670 sulfation reaction Methods 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 229960000257 tiotropium bromide Drugs 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
• 229960000859 tulobuterol Drugs 0.000 description 3
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 2
• YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
• BIIDVVFATFVXTC-UHFFFAOYSA-N 1-bromo-2-ethyl-4-phenylmethoxybenzene Chemical compound C1=C(Br)C(CC)=CC(OCC=2C=CC=CC=2)=C1 BIIDVVFATFVXTC-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• KSZJFHCZTFRRFR-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=NCC2NCNC2=C1 KSZJFHCZTFRRFR-UHFFFAOYSA-N 0.000 description 2
• GGGMBSBQEAELRI-UHFFFAOYSA-N 2-(2-ethyl-5-fluoro-4-phenylmethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1F)B1OC(C(O1)(C)C)(C)C)CC GGGMBSBQEAELRI-UHFFFAOYSA-N 0.000 description 2
• ZZWJKLGCDHYVMB-BWGXUDETSA-N 3-[5-[(1r,2s)-2-(2,2-difluoropropanoylamino)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)propoxy]indazol-1-yl]-n-[(3r)-oxolan-3-yl]benzamide Chemical compound O([C@@H]([C@@H](NC(=O)C(C)(F)F)C)C=1C=C2OCCOC2=CC=1)C(C=C1C=N2)=CC=C1N2C(C=1)=CC=CC=1C(=O)N[C@@H]1CCOC1 ZZWJKLGCDHYVMB-BWGXUDETSA-N 0.000 description 2
• UDKQGFMDBMYVHI-UHFFFAOYSA-N 4-bromo-1-(chloromethyl)-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1CCl UDKQGFMDBMYVHI-UHFFFAOYSA-N 0.000 description 2
• PCFIABOQFAFDAU-UHFFFAOYSA-N 4-bromo-2-fluorobenzoyl chloride Chemical compound FC1=CC(Br)=CC=C1C(Cl)=O PCFIABOQFAFDAU-UHFFFAOYSA-N 0.000 description 2
• VERCIFBQMIUSOI-UHFFFAOYSA-N 6-(2-ethyl-5-fluoro-4-phenylmethoxyphenyl)-1H-indazole Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1F)C1=CC=C2C=NNC2=C1)CC VERCIFBQMIUSOI-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• 241000223602 Alternaria alternata Species 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
• MBWXXAQLCBYOMH-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=CC(=C(C=C1F)C1=CC=C2C(=NN(C2=C1)C1OCCCC1)[Sn](C)(C)C)CC Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1F)C1=CC=C2C(=NN(C2=C1)C1OCCCC1)[Sn](C)(C)C)CC MBWXXAQLCBYOMH-UHFFFAOYSA-N 0.000 description 2
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
• 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 2
• VGARDAWZUXWBBB-UHFFFAOYSA-N CCC(C=C(C=C1)O)=C1C1=CC=C2C(C3=NC(CC(C=O)N(C4)C(C)C)=C4N3)=NNC2=C1 Chemical compound CCC(C=C(C=C1)O)=C1C1=CC=C2C(C3=NC(CC(C=O)N(C4)C(C)C)=C4N3)=NNC2=C1 VGARDAWZUXWBBB-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 208000015943 Coeliac disease Diseases 0.000 description 2
• 206010056979 Colitis microscopic Diseases 0.000 description 2
• 206010011985 Decubitus ulcer Diseases 0.000 description 2
• 229940122858 Elastase inhibitor Drugs 0.000 description 2
• 108050009340 Endothelin Proteins 0.000 description 2
• 102000002045 Endothelin Human genes 0.000 description 2
• 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 208000006968 Helminthiasis Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 2
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• 108090000467 Interferon-beta Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 108090000177 Interleukin-11 Proteins 0.000 description 2
• 102000003815 Interleukin-11 Human genes 0.000 description 2
• 102000013691 Interleukin-17 Human genes 0.000 description 2
• 108050003558 Interleukin-17 Proteins 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 102000000646 Interleukin-3 Human genes 0.000 description 2
• 108010002335 Interleukin-9 Proteins 0.000 description 2
• 102000000585 Interleukin-9 Human genes 0.000 description 2
• 108090000862 Ion Channels Proteins 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
• 206010023439 Kidney transplant rejection Diseases 0.000 description 2
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
• LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
• 108010057466 NF-kappa B Proteins 0.000 description 2
• 102000003945 NF-kappa B Human genes 0.000 description 2
• 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 2
• 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 2
• 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 208000000766 Pityriasis Lichenoides Diseases 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• 201000007902 Primary cutaneous amyloidosis Diseases 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• 206010037083 Prurigo Diseases 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 108010046075 Thymosin Proteins 0.000 description 2
• 102000007501 Thymosin Human genes 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
• 206010047642 Vitiligo Diseases 0.000 description 2
• URWYQGVSPQJGGB-DHUJRADRSA-N [1-[3-[2-chloro-4-[[[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1h-quinolin-5-yl)ethyl]amino]methyl]-5-methoxyanilino]-3-oxopropyl]piperidin-4-yl] n-(2-phenylphenyl)carbamate Chemical compound ClC=1C=C(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)C(OC)=CC=1NC(=O)CCN(CC1)CCC1OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 URWYQGVSPQJGGB-DHUJRADRSA-N 0.000 description 2
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
• SFYAXIFVXBKRPK-QFIPXVFZSA-N abediterol Chemical compound C([C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)NCCCCCCOCC(F)(F)C1=CC=CC=C1 SFYAXIFVXBKRPK-QFIPXVFZSA-N 0.000 description 2
• 229950000192 abediterol Drugs 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 description 2
• 229940019903 aclidinium Drugs 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000008186 active pharmaceutical agent Substances 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 239000000048 adrenergic agonist Substances 0.000 description 2
• 239000000674 adrenergic antagonist Substances 0.000 description 2
• BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• 231100000360 alopecia Toxicity 0.000 description 2
• 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
• 238000010976 amide bond formation reaction Methods 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 230000003092 anti-cytokine Effects 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 2
• 150000001539 azetidines Chemical class 0.000 description 2
• 229950009687 batefenterol Drugs 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 229940092705 beclomethasone Drugs 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 238000010256 biochemical assay Methods 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 229960004436 budesonide Drugs 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 208000000594 bullous pemphigoid Diseases 0.000 description 2
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000002559 chemokine receptor antagonist Substances 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• 208000008609 collagenous colitis Diseases 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 239000002361 compost Substances 0.000 description 2
• 239000007822 coupling agent Substances 0.000 description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• 229950008135 dectrekumab Drugs 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 239000003602 elastase inhibitor Substances 0.000 description 2
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 201000000708 eosinophilic esophagitis Diseases 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 230000000763 evoking effect Effects 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 229960001469 fluticasone furoate Drugs 0.000 description 2
• XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 239000012737 fresh medium Substances 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 229960002885 histidine Drugs 0.000 description 2
• 208000018022 idiopathic eosinophilic pneumonia Diseases 0.000 description 2
• 208000009326 ileitis Diseases 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 229940125369 inhaled corticosteroids Drugs 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
• 229960001888 ipratropium Drugs 0.000 description 2
• 229960002725 isoflurane Drugs 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
• 150000002617 leukotrienes Chemical class 0.000 description 2
• 229950008204 levosalbutamol Drugs 0.000 description 2
• 201000011486 lichen planus Diseases 0.000 description 2
• 229920006008 lipopolysaccharide Polymers 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 208000004341 lymphocytic colitis Diseases 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 238000007885 magnetic separation Methods 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 229960001664 mometasone Drugs 0.000 description 2
• QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
• 229960002744 mometasone furoate Drugs 0.000 description 2
• WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 239000012452 mother liquor Substances 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
• 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 230000007119 pathological manifestation Effects 0.000 description 2
• 230000007310 pathophysiology Effects 0.000 description 2
• HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 description 2
• 229960004439 pemirolast Drugs 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 235000018102 proteins Nutrition 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
• 229940044601 receptor agonist Drugs 0.000 description 2
• 239000000018 receptor agonist Substances 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 229960003254 reslizumab Drugs 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 238000009118 salvage therapy Methods 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 229960003090 seratrodast Drugs 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 238000010898 silica gel chromatography Methods 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 239000012258 stirred mixture Substances 0.000 description 2
• 239000013595 supernatant sample Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
• KLOLZALDXGTNQE-JIDHJSLPSA-N vilanterol trifenate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1.C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 KLOLZALDXGTNQE-JIDHJSLPSA-N 0.000 description 2
• 239000003643 water by type Substances 0.000 description 2
• IXXFZUPTQVDPPK-ZAWHAJPISA-N (1r,2r,4r,6r,7r,8r,10s,13r,14s)-17-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-7-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-10-fluoro-6-methoxy-2,4,6,8,10,14-hexamethyl-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tet Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@](C)(F)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3N=NC(=C3)C=3C=C(N)C=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IXXFZUPTQVDPPK-ZAWHAJPISA-N 0.000 description 1
• LQHDJQIMETZMPH-ZBFHGGJFSA-N (1r,3s)-n-[[4-cyano-2-(trifluoromethyl)phenyl]methyl]-3-[[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino]cyclohexane-1-carboxamide Chemical compound CNC1=NC(C)=NC(N[C@@H]2C[C@@H](CCC2)C(=O)NCC=2C(=CC(=CC=2)C#N)C(F)(F)F)=N1 LQHDJQIMETZMPH-ZBFHGGJFSA-N 0.000 description 1
• CQIBMEIJDDUKHP-BAHZVNHDSA-N (1s,3s,4r)-4-[(3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methylidene-3,3a,4,5,6,7-hexahydro-2h-inden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexan-1-ol;acetic acid Chemical compound CC(O)=O.C[C@]1([C@H]2CC[C@]3([C@H]([C@@H]2CN)CCC3=C)C)CC[C@H](O)C[C@@H]1CO CQIBMEIJDDUKHP-BAHZVNHDSA-N 0.000 description 1
• KCSNGWMKFYVMKF-HGYIIGRXSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(C)=O)CC1=CC=CC=C1 KCSNGWMKFYVMKF-HGYIIGRXSA-N 0.000 description 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• VXBNTHRZPJLRSS-PTCSXESPSA-N (2s)-2-[(2r,3r,4s,5s,6r)-3-benzoyloxy-2-[(1r,2r,3s,5r)-3-[(2,4-dioxo-1h-pyrimidine-6-carbonyl)amino]-5-[2-[[2-[2-[2-oxo-2-[(3,6,8-trisulfonaphthalen-1-yl)amino]ethoxy]ethoxy]acetyl]amino]ethylcarbamoyl]-2-[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2- Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@@H](CC3CCCCC3)C(O)=O)[C@@H](O)[C@@H](CO)O2)OC(=O)C=2C=CC=CC=2)C[C@H](C(=O)NCCNC(=O)COCCOCC(=O)NC=2C3=C(C=C(C=C3C=C(C=2)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C[C@@H]1NC(=O)C1=CC(=O)NC(=O)N1 VXBNTHRZPJLRSS-PTCSXESPSA-N 0.000 description 1
• NSPHQWLKCGGCQR-DLJDZFDSSA-N (2s)-2-[[(1r,4s,7s,10s,13s,16r,21r,27s,34r,37s,40s)-10-(2-amino-2-oxoethyl)-34-[[(2s)-4-carboxy-2-[[(2s)-3-carboxy-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-37-(2-carboxyethyl)-27-[(1r)-1-hydroxyethyl]-4-methyl-40-(2-methylp Chemical compound N1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)CSSC[C@@H]2NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC2=O NSPHQWLKCGGCQR-DLJDZFDSSA-N 0.000 description 1
• LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• QIDYUNXQPQEJEC-IBGZPJMESA-N (4S)-6-chloro-7-[4-[2-(4-chloro-2-methoxyphenyl)ethylcarbamoyl]phenoxy]-3,4-dihydro-2H-chromene-4-carboxylic acid Chemical compound COc1cc(Cl)ccc1CCNC(=O)c1ccc(Oc2cc3OCC[C@H](C(O)=O)c3cc2Cl)cc1 QIDYUNXQPQEJEC-IBGZPJMESA-N 0.000 description 1
• GWDXWHWBNRSNAV-SFHVURJKSA-N (6S)-2-[6-(2-ethyl-4-hydroxyphenyl)-1H-indazol-3-yl]-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid Chemical compound C(C)C1=C(C=CC(=C1)O)C1=CC=C2C(=NNC2=C1)C1=NC2=C(CN[C@@H](C2)C(=O)O)N1 GWDXWHWBNRSNAV-SFHVURJKSA-N 0.000 description 1
• DHTFVEKRZYCKSI-YFKPBYRVSA-N (6S)-2-iodo-3,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5,6-dicarboxylic acid Chemical compound OC(=O)[C@@H]1Cc2nc(I)[nH]c2CN1C(O)=O DHTFVEKRZYCKSI-YFKPBYRVSA-N 0.000 description 1
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• SZNJINHODJLULD-SDNWHVSQSA-N (e)-3-(4-hydroxy-3,5-dimethoxyphenyl)-n-(4-hydroxy-1-methyl-3-octoxy-2-oxoquinolin-7-yl)prop-2-enamide Chemical compound C1=C2N(C)C(=O)C(OCCCCCCCC)=C(O)C2=CC=C1NC(=O)\C=C\C1=CC(OC)=C(O)C(OC)=C1 SZNJINHODJLULD-SDNWHVSQSA-N 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• PXRYYARWCNIUKT-UHFFFAOYSA-M 1,1-diethyl-4-phenyl-1,4-diazepan-1-ium 4-methylbenzenesulfonate Chemical compound Cc1ccc(cc1)S([O-])(=O)=O.CC[N+]1(CC)CCCN(CC1)c1ccccc1 PXRYYARWCNIUKT-UHFFFAOYSA-M 0.000 description 1
• HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
• HLGVZNIODPNAME-UHFFFAOYSA-N 1-(1H-indazol-3-yl)-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine Chemical compound N1N=C(C2=CC=CC=C12)N1C=NC=2CNCCC=21 HLGVZNIODPNAME-UHFFFAOYSA-N 0.000 description 1
• NGYNBSHYFOFVLS-LBPRGKRZSA-N 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@@H]2CNCCC2)=C1O NGYNBSHYFOFVLS-LBPRGKRZSA-N 0.000 description 1
• 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• FOCKIYZLSZKVDH-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-b]pyridine Chemical group N1C=CC=C2NCNC21 FOCKIYZLSZKVDH-UHFFFAOYSA-N 0.000 description 1
• BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
• RVLCUCVJZVRNDC-IMJSIDKUSA-N 2-[(2s,5s)-5-methyl-3,6-dioxopiperazin-2-yl]acetic acid Chemical compound C[C@@H]1NC(=O)[C@H](CC(O)=O)NC1=O RVLCUCVJZVRNDC-IMJSIDKUSA-N 0.000 description 1
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
• GFPPXZDRVCSVNR-UHFFFAOYSA-N 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC=CN=C2N1CC1=CC=C(S(C)(=O)=O)C=C1C(F)(F)F GFPPXZDRVCSVNR-UHFFFAOYSA-N 0.000 description 1
• DOSMHBDKKKMIEF-UHFFFAOYSA-N 2-[3-(diethylamino)-6-diethylazaniumylidenexanthen-9-yl]-5-[3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propylsulfamoyl]benzenesulfonate Chemical compound C1=CC(=[N+](CC)CC)C=C2OC3=CC(N(CC)CC)=CC=C3C(C=3C(=CC(=CC=3)S(=O)(=O)NCCCN3C4=CC=CC=C4C(C=4C(NC(=O)C=4C=4C5=CC=CC=C5N(C)C=4)=O)=C3)S([O-])(=O)=O)=C21 DOSMHBDKKKMIEF-UHFFFAOYSA-N 0.000 description 1
• UBBJJBFUHAYINW-UHFFFAOYSA-N 2-[4-amino-3-chloro-5-(trifluoromethyl)phenyl]-2-(tert-butylamino)ethanol;hydrochloride Chemical compound Cl.CC(C)(C)NC(CO)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 UBBJJBFUHAYINW-UHFFFAOYSA-N 0.000 description 1
• FATGTHLOZSXOBC-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1CC1=CC=C(C=CC=C2)C2=N1 FATGTHLOZSXOBC-UHFFFAOYSA-N 0.000 description 1
• OANCEOSLKSTLTA-REWPJTCUSA-N 2-[[(7s)-7-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-n,n-dimethylacetamide Chemical compound C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)N(C)C)=CC=C(O)C(CCO)=C1 OANCEOSLKSTLTA-REWPJTCUSA-N 0.000 description 1
• JJBCTCGUOQYZHK-UHFFFAOYSA-N 2-acetyloxybenzoate;(5-amino-1-carboxypentyl)azanium Chemical compound OC(=O)C(N)CCCC[NH3+].CC(=O)OC1=CC=CC=C1C([O-])=O JJBCTCGUOQYZHK-UHFFFAOYSA-N 0.000 description 1
• 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• HBZAZSCNDMDWEU-WREZULKGSA-N 3,5-diamino-6-chloro-n-[n'-[4-[4-[2-[hexyl-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]amino]ethoxy]phenyl]butyl]carbamimidoyl]pyrazine-2-carboxamide Chemical compound C1=CC(OCCN(CCCCCC)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C1CCCCNC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N HBZAZSCNDMDWEU-WREZULKGSA-N 0.000 description 1
• JMWYNUHGKFJVIB-QGFXQWJDSA-N 3-[(3R,9S,12S,15S,18S,24S,30S,33S,36S,39S,42S,45S,48S)-12-(4-aminobutyl)-15-(3-amino-3-oxopropyl)-30-[(2S)-butan-2-yl]-39-[(1R)-1-hydroxyethyl]-33-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-36-methyl-45-octyl-2,8,11,14,17,23,29,32,35,38,41,44,47-tridecaoxo-1,7,10,13,16,22,28,31,34,37,40,43,46-tridecazapentacyclo[46.3.0.03,7.018,22.024,28]henpentacontan-42-yl]propanoic acid Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)CCCCCCCC)C1=CC=C(O)C=C1 JMWYNUHGKFJVIB-QGFXQWJDSA-N 0.000 description 1
• YVPGZQLRPAGKLA-UHFFFAOYSA-N 3-[1-(4-carbamoyl-2-methylphenyl)-5-(4-imidazol-1-ylphenyl)pyrrol-2-yl]propanoic acid Chemical compound CC1=CC(C(N)=O)=CC=C1N1C(C=2C=CC(=CC=2)N2C=NC=C2)=CC=C1CCC(O)=O YVPGZQLRPAGKLA-UHFFFAOYSA-N 0.000 description 1
• HWNIPKHEEVNHMN-UHFFFAOYSA-N 3-[4-[2-[1-benzhydryl-5-chloro-2-[2-[[2-(trifluoromethyl)phenyl]methylsulfonylamino]ethyl]indol-3-yl]ethylsulfonyl]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1S(=O)(=O)CCC(C1=CC(Cl)=CC=C1N1C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1CCNS(=O)(=O)CC1=CC=CC=C1C(F)(F)F HWNIPKHEEVNHMN-UHFFFAOYSA-N 0.000 description 1
• ULMFXAMQUGLVGA-LJQANCHMSA-N 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-n-[(2r)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide Chemical compound C=1C=C(CC=2C3=CC(=CC=C3N(C)C=2)C(=O)NC[C@H](C)CC(F)(F)F)C(OC)=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C ULMFXAMQUGLVGA-LJQANCHMSA-N 0.000 description 1
• USHQRIKZLHNPQR-JTQLQIEISA-N 3-amino-6-methoxy-n-[(2s)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide Chemical compound COC1=NC(C(=O)NC[C@](C)(O)C(F)(F)F)=C(N)C=C1C(F)(F)F USHQRIKZLHNPQR-JTQLQIEISA-N 0.000 description 1
• KZYAHEIPPAPADQ-UHFFFAOYSA-N 4-(4-chloro-2-fluorophenyl)-2-(2-chloropyridin-4-yl)-n-(6-fluoro-1h-indazol-5-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide Chemical compound N1C(C)=C(C(=O)NC=2C(=CC=3NN=CC=3C=2)F)C(C=2C(=CC(Cl)=CC=2)F)N=C1C1=CC=NC(Cl)=C1 KZYAHEIPPAPADQ-UHFFFAOYSA-N 0.000 description 1
• MDHKCIIEVIPVLU-JERHFGHZSA-M 4-[(1r)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide Chemical compound [Br-].C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1.C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 MDHKCIIEVIPVLU-JERHFGHZSA-M 0.000 description 1
• ZQQSRVPOAHYHEL-UHFFFAOYSA-N 4-bromo-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1F ZQQSRVPOAHYHEL-UHFFFAOYSA-N 0.000 description 1
• AGPCZZAYJRAENV-UHFFFAOYSA-N 4-bromo-5-ethyl-2-fluorophenol Chemical compound CCC1=CC(O)=C(F)C=C1Br AGPCZZAYJRAENV-UHFFFAOYSA-N 0.000 description 1
• DWOZNANUEDYIOF-UHFFFAOYSA-L 4-ditert-butylphosphanyl-n,n-dimethylaniline;dichloropalladium Chemical compound Cl[Pd]Cl.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 DWOZNANUEDYIOF-UHFFFAOYSA-L 0.000 description 1
• 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
• LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
• RFAYDBLGPUAICX-UHFFFAOYSA-N 6-(2-ethyl-5-fluoro-4-phenylmethoxyphenyl)-1-(oxan-2-yl)indazole Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1F)C1=CC=C2C=NN(C2=C1)C1OCCCC1)CC RFAYDBLGPUAICX-UHFFFAOYSA-N 0.000 description 1
• XSMJTRACFNYDFT-UHFFFAOYSA-N 6-(2-ethyl-5-fluoro-4-phenylmethoxyphenyl)-3-iodo-1-(oxan-2-yl)indazole Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1F)C1=CC=C2C(=NN(C2=C1)C1OCCCC1)I)CC XSMJTRACFNYDFT-UHFFFAOYSA-N 0.000 description 1
• XLLRREYHAULADB-UHFFFAOYSA-N 6-(2-ethyl-5-fluoro-4-phenylmethoxyphenyl)-3-iodo-2H-indazole Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1F)C1=CC=C2C(=NNC2=C1)I)CC XLLRREYHAULADB-UHFFFAOYSA-N 0.000 description 1
• UBLOHCIYTDRGJH-UHFFFAOYSA-N 6-[2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-4-oxoquinazolin-5-yl]-n,n-bis(2-methoxyethyl)hex-5-ynamide Chemical compound C=1C=CC=C(Cl)C=1CN1C(=O)C=2C(C#CCCCC(=O)N(CCOC)CCOC)=CC=CC=2N=C1CN(C1=NC=NC(N)=C11)N=C1C1=CC=CC(O)=C1 UBLOHCIYTDRGJH-UHFFFAOYSA-N 0.000 description 1
• LFMPVTVPXHNXOT-HNNXBMFYSA-N 6-amino-2-[(2s)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7h-purin-8-one Chemical compound C12=NC(O[C@@H](C)CCC)=NC(N)=C2NC(=O)N1CCCCCN1CCCCC1 LFMPVTVPXHNXOT-HNNXBMFYSA-N 0.000 description 1
• XUSDKDVQICYOIP-UHFFFAOYSA-N 6-bromo-1-(oxan-2-yl)indazole Chemical compound C12=CC(Br)=CC=C2C=NN1C1CCCCO1 XUSDKDVQICYOIP-UHFFFAOYSA-N 0.000 description 1
• 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 229940121819 ATPase inhibitor Drugs 0.000 description 1
• 229940122578 Acetylcholine receptor agonist Drugs 0.000 description 1
• 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
• 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 229940123470 Alcohol dehydrogenase 5 inhibitor Drugs 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 238000012815 AlphaLISA Methods 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 102100032187 Androgen receptor Human genes 0.000 description 1
• 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
• 102400000345 Angiotensin-2 Human genes 0.000 description 1
• 101800000733 Angiotensin-2 Proteins 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 108090000672 Annexin A5 Proteins 0.000 description 1
• 102000004121 Annexin A5 Human genes 0.000 description 1
• 241000269837 Artemisia dubia Species 0.000 description 1
• 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 101150082778 BMP10 gene Proteins 0.000 description 1
• 101150038684 BMP15 gene Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
• 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
• 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
• 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• WNXFAZDCTIYMPC-JYXQOGIISA-N CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)C1NNC2CC(CCC12)c1cc(F)c(O)cc1CC Chemical compound CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C)(C1)N(C)C)C1NNC2CC(CCC12)c1cc(F)c(O)cc1CC WNXFAZDCTIYMPC-JYXQOGIISA-N 0.000 description 1
• WWEWCYYDKYAQTQ-ATJOBZSNSA-N CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C1)N(C)C)C1NNC2CC(CCC12)c1cc(F)c(O)cc1CC Chemical compound CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C1)N(C)C)C1NNC2CC(CCC12)c1cc(F)c(O)cc1CC WWEWCYYDKYAQTQ-ATJOBZSNSA-N 0.000 description 1
• 101150112860 CCL26 gene Proteins 0.000 description 1
• DBMKRSLAJVGDQY-HEZITFPNSA-N CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C1)N(C)C)C1NNC2CC(CCC12)c1cc(F)c(O)cc1CC Chemical compound CCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C1)N(C)C)C1NNC2CC(CCC12)c1cc(F)c(O)cc1CC DBMKRSLAJVGDQY-HEZITFPNSA-N 0.000 description 1
• 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 1
• 229940044663 CMP-001 Drugs 0.000 description 1
• ZNKWRAKPQQZLNX-ZDQHWEPJSA-N CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 ZNKWRAKPQQZLNX-ZDQHWEPJSA-N 0.000 description 1
• 229940124003 CRTH2 antagonist Drugs 0.000 description 1
• 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
• 229940045513 CTLA4 antagonist Drugs 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 101100268548 Caenorhabditis elegans apl-1 gene Proteins 0.000 description 1
• 101100135867 Caenorhabditis elegans pde-3 gene Proteins 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 229940122079 Cathepsin G inhibitor Drugs 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
• 102000052603 Chaperonins Human genes 0.000 description 1
• 229940125842 Chitinase inhibitor Drugs 0.000 description 1
• 102000012286 Chitinases Human genes 0.000 description 1
• 108010022172 Chitinases Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 102000016918 Complement C3 Human genes 0.000 description 1
• 108010028780 Complement C3 Proteins 0.000 description 1
• 229940124073 Complement inhibitor Drugs 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 101800000414 Corticotropin Proteins 0.000 description 1
• 108010074311 Corticotropin Receptors Proteins 0.000 description 1
• 101710095468 Cyclase Proteins 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 102100038496 Cysteinyl leukotriene receptor 1 Human genes 0.000 description 1
• 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• 101710114790 Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 101710137619 DNA gyrase inhibitor Proteins 0.000 description 1
• 229940087106 DNA topoisomerase IV inhibitor Drugs 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
• 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 description 1
• 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 229940123546 E-selectin antagonist Drugs 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 102000016942 Elastin Human genes 0.000 description 1
• 108010014258 Elastin Proteins 0.000 description 1
• 206010058838 Enterocolitis infectious Diseases 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 102100023688 Eotaxin Human genes 0.000 description 1
• 101710139422 Eotaxin Proteins 0.000 description 1
• 229940122183 Epoxide hydrolase inhibitor Drugs 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 206010016936 Folliculitis Diseases 0.000 description 1
• 229940123570 Fyn tyrosine kinase inhibitor Drugs 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000004610 GATA3 Transcription Factor Human genes 0.000 description 1
• 108010003338 GATA3 Transcription Factor Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 229940123127 Glucocorticoid agonist Drugs 0.000 description 1
• 102000004547 Glucosylceramidase Human genes 0.000 description 1
• 108010017544 Glucosylceramidase Proteins 0.000 description 1
• 102000018899 Glutamate Receptors Human genes 0.000 description 1
• 108010027915 Glutamate Receptors Proteins 0.000 description 1
• 229940122247 Glutathione reductase inhibitor Drugs 0.000 description 1
• 108060003393 Granulin Proteins 0.000 description 1
• 201000005708 Granuloma Annulare Diseases 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
• 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
• 229940119240 Histamine H4 receptor antagonist Drugs 0.000 description 1
• 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
• 102000011423 Histone Deacetylase 2 Human genes 0.000 description 1
• 108010023981 Histone Deacetylase 2 Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
• 101000882759 Homo sapiens Cysteinyl leukotriene receptor 1 Proteins 0.000 description 1
• 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 description 1
• 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 1
• 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
• 101001019591 Homo sapiens Interleukin-18-binding protein Proteins 0.000 description 1
• 101001008922 Homo sapiens Kallikrein-11 Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
• 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 101150083678 IL2 gene Proteins 0.000 description 1
• 102000009490 IgG Receptors Human genes 0.000 description 1
• 108010073807 IgG Receptors Proteins 0.000 description 1
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 229940122355 Insulin sensitizer Drugs 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000003777 Interleukin-1 beta Human genes 0.000 description 1
• 108090000193 Interleukin-1 beta Proteins 0.000 description 1
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
• 102000004553 Interleukin-11 Receptors Human genes 0.000 description 1
• 108010017521 Interleukin-11 Receptors Proteins 0.000 description 1
• 102000004554 Interleukin-17 Receptors Human genes 0.000 description 1
• 108010017525 Interleukin-17 Receptors Proteins 0.000 description 1
• 102000003810 Interleukin-18 Human genes 0.000 description 1
• 108090000171 Interleukin-18 Proteins 0.000 description 1
• 102100035017 Interleukin-18-binding protein Human genes 0.000 description 1
• 102100021596 Interleukin-31 Human genes 0.000 description 1
• 101710181613 Interleukin-31 Proteins 0.000 description 1
• 108010067003 Interleukin-33 Proteins 0.000 description 1
• 102000017761 Interleukin-33 Human genes 0.000 description 1
• 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
• 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• 102100027612 Kallikrein-11 Human genes 0.000 description 1
• 102100020880 Kit ligand Human genes 0.000 description 1
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
• 229940121930 L-selectin antagonist Drugs 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000002139 L01XE22 - Masitinib Substances 0.000 description 1
• 101150043981 LOXL2 gene Proteins 0.000 description 1
• 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
• GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
• 102100023758 Leukotriene C4 synthase Human genes 0.000 description 1
• OTZRAYGBFWZKMX-SHSCPDMUSA-N Leukotriene E4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(N)C(=O)O)C(O)CCCC(=O)O OTZRAYGBFWZKMX-SHSCPDMUSA-N 0.000 description 1
• 206010024434 Lichen sclerosus Diseases 0.000 description 1
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
• 208000024078 Localized pagetoid reticulosis Diseases 0.000 description 1
• 208000032376 Lung infection Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 229940122696 MAP kinase inhibitor Drugs 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 229940082332 Muscarinic M1 receptor antagonist Drugs 0.000 description 1
• 229940123467 Muscarinic M2 receptor antagonist Drugs 0.000 description 1
• 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 description 1
• 229940117926 Muscarinic M4 receptor antagonist Drugs 0.000 description 1
• 108010008409 Muscarinic M5 Receptor Proteins 0.000 description 1
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 102100031789 Myeloid-derived growth factor Human genes 0.000 description 1
• 108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 1
• 102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 1
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical group CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
• LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• KSIJIGHGXBEURD-UHFFFAOYSA-N N1(CCCCC1)CCOC1=CC=C(C=C1)C1=NN(C(=C1)C1=CC=C(C=C1)O)C1=CC=C(C=C1)O Chemical compound N1(CCCCC1)CCOC1=CC=C(C=C1)C1=NN(C(=C1)C1=CC=C(C=C1)O)C1=CC=C(C=C1)O KSIJIGHGXBEURD-UHFFFAOYSA-N 0.000 description 1
• 102100033457 NF-kappa-B inhibitor beta Human genes 0.000 description 1
• 101710204094 NF-kappa-B inhibitor beta Proteins 0.000 description 1
• 108091008877 NK cell receptors Proteins 0.000 description 1
• 108020001621 Natriuretic Peptide Proteins 0.000 description 1
• 102000004571 Natriuretic peptide Human genes 0.000 description 1
• 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
• 201000009053 Neurodermatitis Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 229940081142 Opioid growth factor receptor agonist Drugs 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 229940121825 P-selectin antagonist Drugs 0.000 description 1
• 102100040460 P2X purinoceptor 3 Human genes 0.000 description 1
• 101710189970 P2X purinoceptor 3 Proteins 0.000 description 1
• 102100032341 PCNA-interacting partner Human genes 0.000 description 1
• 101710196737 PCNA-interacting partner Proteins 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 108010014865 PLIalpha Proteins 0.000 description 1
• 208000002541 Pagetoid Reticulosis Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 101150034459 Parpbp gene Proteins 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 101710167374 Peptidase 1 Proteins 0.000 description 1
• 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
• 229940049937 Pgp inhibitor Drugs 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
• 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
• 229940123898 Phospholipase A2 inhibitor Drugs 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• QSXMZJGGEWYVCN-UHFFFAOYSA-N Pirbuterol acetate Chemical compound CC(O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 QSXMZJGGEWYVCN-UHFFFAOYSA-N 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 229940124090 Platelet-derived growth factor (PDGF) receptor antagonist Drugs 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 206010036783 Proctitis ulcerative Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• NFQIAEMCQGTTIR-UHFFFAOYSA-N Repirinast Chemical compound C12=CC=C(C)C(C)=C2NC(=O)C2=C1OC(C(=O)OCCC(C)C)=CC2=O NFQIAEMCQGTTIR-UHFFFAOYSA-N 0.000 description 1
• 102000014400 SH2 domains Human genes 0.000 description 1
• 108050003452 SH2 domains Proteins 0.000 description 1
• 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
• 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• IHAXLPDVOWLUOS-UHFFFAOYSA-N Setipiprant Chemical compound C1=CC=C2C(C(=O)N3CCC=4N(C5=CC=C(F)C=C5C=4C3)CC(=O)O)=CC=CC2=C1 IHAXLPDVOWLUOS-UHFFFAOYSA-N 0.000 description 1
• 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• 206010041660 Splenomegaly Diseases 0.000 description 1
• 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
• 108010039445 Stem Cell Factor Proteins 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• DYZJXZOQQRXDLE-UHFFFAOYSA-O Suplatast tosilate Chemical compound CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 DYZJXZOQQRXDLE-UHFFFAOYSA-O 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 229940124615 TLR 7 agonist Drugs 0.000 description 1
• 229940124614 TLR 8 agonist Drugs 0.000 description 1
• 101150038509 TLR9 gene Proteins 0.000 description 1
• 206010043391 Thalassaemia beta Diseases 0.000 description 1
• 108010069102 Thromboxane-A synthase Proteins 0.000 description 1
• KPWYNAGOBXLMSE-UHFFFAOYSA-N Tipelukast Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1SCCCOC1=CC=C(C(C)=O)C(OCCCC(O)=O)=C1CCC KPWYNAGOBXLMSE-UHFFFAOYSA-N 0.000 description 1
• 239000004012 Tofacitinib Substances 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000000887 Transcription factor STAT Human genes 0.000 description 1
• 108050007918 Transcription factor STAT Proteins 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 102000013394 Troponin I Human genes 0.000 description 1
• 108010065729 Troponin I Proteins 0.000 description 1
• 102000004987 Troponin T Human genes 0.000 description 1
• 108090001108 Troponin T Proteins 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
• 102000003848 Uteroglobin Human genes 0.000 description 1
• 108090000203 Uteroglobin Proteins 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
• VCFBPAOSTLMYIV-SANMLTNESA-N [(1s)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-(cyclopropylmethoxy)-4-(methanesulfonamido)benzoate Chemical compound CS(=O)(=O)NC1=CC=C(C(=O)O[C@@H](CC=2C(=C[N+]([O-])=CC=2Cl)Cl)C=2C=C(OCC3CC3)C(OC(F)F)=CC=2)C=C1OCC1CC1 VCFBPAOSTLMYIV-SANMLTNESA-N 0.000 description 1
• ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 1
• FYDWDCIFZSGNBU-UHFFFAOYSA-N [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] n-(2-phenylphenyl)carbamate Chemical compound C=1C=C(CN2CCC(CC2)C(N)=O)C=CC=1C(=O)N(C)CCN(CC1)CCC1OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 FYDWDCIFZSGNBU-UHFFFAOYSA-N 0.000 description 1
• REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
• KAVVKRQBEAWLIE-MHZLTWQESA-N [3-(dimethylamino)-3-methylazetidin-1-yl]-[(6S)-2-[6-(2-ethyl-4-hydroxyphenyl)-1H-indazol-3-yl]-5-propan-2-yl-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-6-yl]methanone Chemical compound CN(C1(CN(C1)C(=O)[C@@H]1CC2=C(CN1C(C)C)NC(=N2)C1=NNC2=CC(=CC=C12)C1=C(C=C(C=C1)O)CC)C)C KAVVKRQBEAWLIE-MHZLTWQESA-N 0.000 description 1
• LXCJYFUAMDZSGA-MHZLTWQESA-N [3-(dimethylamino)-3-methylazetidin-1-yl]-[(6S)-2-[6-(2-ethyl-4-hydroxyphenyl)-1H-indazol-3-yl]-5-propyl-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-6-yl]methanone Chemical compound CN(C1(CN(C1)C(=O)[C@@H]1CC2=C(CN1CCC)NC(=N2)C1=NNC2=CC(=CC=C12)C1=C(C=C(C=C1)O)CC)C)C LXCJYFUAMDZSGA-MHZLTWQESA-N 0.000 description 1
• WIICDYUXOKRMJM-SANMLTNESA-N [3-(dimethylamino)-3-methylazetidin-1-yl]-[(6S)-2-[6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl]-5-propan-2-yl-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-6-yl]methanone Chemical compound CN(C1(CN(C1)C(=O)[C@@H]1CC2=C(CN1C(C)C)NC(=N2)C1=NNC2=CC(=CC=C12)C1=C(C=C(C(=C1)F)O)CC)C)C WIICDYUXOKRMJM-SANMLTNESA-N 0.000 description 1
• RINWDSCUVKTALQ-SANMLTNESA-N [3-(dimethylamino)-3-methylazetidin-1-yl]-[(6S)-5-ethyl-2-[6-(2-ethyl-4-hydroxyphenyl)-1H-indazol-3-yl]-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-6-yl]methanone Chemical compound CN(C1(CN(C1)C(=O)[C@@H]1CC2=C(CN1CC)NC(=N2)C1=NNC2=CC(=CC=C12)C1=C(C=C(C=C1)O)CC)C)C RINWDSCUVKTALQ-SANMLTNESA-N 0.000 description 1
• IOVFFTMQWCOHDE-MHZLTWQESA-N [3-(dimethylamino)azetidin-1-yl]-[(6S)-2-[6-(2-ethyl-4-hydroxyphenyl)-1H-indazol-3-yl]-5-propyl-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-6-yl]methanone Chemical compound CN(C1CN(C1)C(=O)[C@@H]1CC2=C(CN1CCC)NC(=N2)C1=NNC2=CC(=CC=C12)C1=C(C=C(C=C1)O)CC)C IOVFFTMQWCOHDE-MHZLTWQESA-N 0.000 description 1
• YAHQISLGSOFLRU-SANMLTNESA-N [3-(dimethylamino)azetidin-1-yl]-[(6S)-5-ethyl-2-[6-(2-ethyl-4-hydroxyphenyl)-1H-indazol-3-yl]-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-6-yl]methanone Chemical compound CN(C1CN(C1)C(=O)[C@@H]1CC2=C(CN1CC)NC(=N2)C1=NNC2=CC(=CC=C12)C1=C(C=C(C=C1)O)CC)C YAHQISLGSOFLRU-SANMLTNESA-N 0.000 description 1
• AGQFLEFSRLZALV-KQYNXXCUSA-N [9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-iminopurin-3-yl]phosphonic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N(C=NC2=N)P(O)(O)=O)=C2N=C1 AGQFLEFSRLZALV-KQYNXXCUSA-N 0.000 description 1
• 229960003697 abatacept Drugs 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• TVWAEQRFKRTYIG-JIDHJSLPSA-N acetic acid;4-[(1r)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound CC(O)=O.C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 TVWAEQRFKRTYIG-JIDHJSLPSA-N 0.000 description 1
• RAFKCLFWELPONH-UHFFFAOYSA-N acetonitrile;dichloromethane Chemical compound CC#N.ClCCl RAFKCLFWELPONH-UHFFFAOYSA-N 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 229940099550 actimmune Drugs 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 239000000332 adrenergic beta-1 receptor antagonist Substances 0.000 description 1
• ISBHYKVAFKTATD-SNVBAGLBSA-N adriforant Chemical compound C1[C@H](NC)CCN1C1=CC(NCC2CC2)=NC(N)=N1 ISBHYKVAFKTATD-SNVBAGLBSA-N 0.000 description 1
• 239000013567 aeroallergen Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 208000037883 airway inflammation Diseases 0.000 description 1
• 229940083712 aldosterone antagonist Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
• 229960005174 ambroxol Drugs 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 229960004238 anakinra Drugs 0.000 description 1
• 239000002269 analeptic agent Substances 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 229950004189 andecaliximab Drugs 0.000 description 1
• 108010080146 androgen receptors Proteins 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000006909 anti-apoptosis Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000011230 antibody-based therapy Methods 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229960001164 apremilast Drugs 0.000 description 1
• IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229960001692 arformoterol Drugs 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 108010038239 aspartyl-alanyl-diketopiperazine Proteins 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 239000012911 assay medium Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 229940098165 atrovent Drugs 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
• 229960004099 azithromycin Drugs 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 229950003452 bedoradrine Drugs 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 125000001743 benzylic group Chemical group 0.000 description 1
• 229940125388 beta agonist Drugs 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
• 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
• ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 description 1
• 229960004314 bilastine Drugs 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
• 229960003065 bosentan Drugs 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• AEXFXNFMSAAELR-RXVVDRJESA-N brensocatib Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 AEXFXNFMSAAELR-RXVVDRJESA-N 0.000 description 1
• 229960003735 brodalumab Drugs 0.000 description 1
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• HQABUPZFAYXKJW-UHFFFAOYSA-O butylazanium Chemical compound CCCC[NH3+] HQABUPZFAYXKJW-UHFFFAOYSA-O 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229960001838 canakinumab Drugs 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 238000012754 cardiac puncture Methods 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 229940125400 channel inhibitor Drugs 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• KEWHKYJURDBRMN-XSAPEOHZSA-M chembl2134724 Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-XSAPEOHZSA-M 0.000 description 1
• 239000013000 chemical inhibitor Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 208000019069 chronic childhood arthritis Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 229960002173 citrulline Drugs 0.000 description 1
• 235000013477 citrulline Nutrition 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• RSOZZQTUMVBTMR-XGUNBQNXSA-N colforsin daropate Chemical compound O[C@H]([C@@]12C)CCC(C)(C)[C@@H]1[C@H](OC(=O)CCN(C)C)[C@H](OC(C)=O)[C@]1(C)[C@]2(O)C(=O)C[C@](C)(C=C)O1 RSOZZQTUMVBTMR-XGUNBQNXSA-N 0.000 description 1
• 229950005198 colforsin daropate Drugs 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 239000004074 complement inhibitor Substances 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000012050 conventional carrier Substances 0.000 description 1
• 238000011443 conventional therapy Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 229960000265 cromoglicic acid Drugs 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• GORAHSAIYZMTHZ-LBFSFEBVSA-N dalazatide Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSCC3C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4N=CNC=4)NC(=O)[C@H](CCCCN)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@@](CCCNC(N)=N)(OCCOCCN)N(C(C)=O)C(=O)[C@@H](N)CC=1C=CC(OP(O)(O)=O)=CC=1)C(N)=O)[C@@H](C)O)C1=CC=CC=C1 GORAHSAIYZMTHZ-LBFSFEBVSA-N 0.000 description 1
• 229950001360 dalazatide Drugs 0.000 description 1
• 229950003518 danirixin Drugs 0.000 description 1
• 229960001145 deflazacort Drugs 0.000 description 1
• FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• VGBVAARMQYYITG-DESRROFGSA-N des-acetyl msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 VGBVAARMQYYITG-DESRROFGSA-N 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
• PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
• 229950004920 dexpramipexole Drugs 0.000 description 1
• FASDKYOPVNHBLU-SSDOTTSWSA-N dexpramipexole Chemical compound C1[C@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-SSDOTTSWSA-N 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• NALBLJLOBICXRH-UHFFFAOYSA-N dinitrogen monohydride Chemical compound N=[N] NALBLJLOBICXRH-UHFFFAOYSA-N 0.000 description 1
• FVTWTVQXNAJTQP-UHFFFAOYSA-N diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol Chemical compound C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 FVTWTVQXNAJTQP-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• 108010067396 dornase alfa Proteins 0.000 description 1
• 229960000533 dornase alfa Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 229950003468 dupilumab Drugs 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 229960001971 ebastine Drugs 0.000 description 1
• MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
• 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
• JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
• 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
• 229920002549 elastin Polymers 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 229960000325 emedastine Drugs 0.000 description 1
• KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• CSOBIBXVIYAXFM-BYNJWEBRSA-N ensifentrine Chemical compound c-12cc(OC)c(OC)cc2CCn(c(n2CCNC(N)=O)=O)c-1c\c2=N/c1c(C)cc(C)cc1C CSOBIBXVIYAXFM-BYNJWEBRSA-N 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 229960003449 epinastine Drugs 0.000 description 1
• WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
• 229960004770 esomeprazole Drugs 0.000 description 1
• SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 229960001022 fenoterol Drugs 0.000 description 1
• 229950003562 fevipiprant Drugs 0.000 description 1
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
• 229960003592 fexofenadine Drugs 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 239000012997 ficoll-paque Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 229940085861 flovent Drugs 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229960000676 flunisolide Drugs 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 238000005755 formation reaction Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 229940069042 gamunex Drugs 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000009650 gentamicin protection assay Methods 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000002748 glycoprotein P inhibitor Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000005337 ground glass Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000002271 gyrase inhibitor Substances 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 229940125926 hemoglobin modulator Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 239000000938 histamine H1 antagonist Substances 0.000 description 1
• 239000003396 histamine H4 receptor antagonist Substances 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
• 102000044064 human CCL17 Human genes 0.000 description 1
• 102000045535 human TSLP Human genes 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 230000004047 hyperresponsiveness Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 208000024364 idiopathic hypereosinophilic syndrome Diseases 0.000 description 1
• 229960002240 iloprost Drugs 0.000 description 1
• HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• SQKXYSGRELMAAU-UHFFFAOYSA-N imidafenacin Chemical compound CC1=NC=CN1CCC(C(N)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 SQKXYSGRELMAAU-UHFFFAOYSA-N 0.000 description 1
• 229950005396 imidafenacin Drugs 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 230000007365 immunoregulation Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 229960004735 indacaterol maleate Drugs 0.000 description 1
• IREJFXIHXRZFER-PCBAQXHCSA-N indacaterol maleate Chemical compound OC(=O)\C=C/C(O)=O.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 IREJFXIHXRZFER-PCBAQXHCSA-N 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000027139 infectious colitis Diseases 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 102000006029 inositol monophosphatase Human genes 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000035990 intercellular signaling Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 108010042414 interferon gamma-1b Proteins 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 229940100602 interleukin-5 Drugs 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 229960001361 ipratropium bromide Drugs 0.000 description 1
• LHLMOSXCXGLMMN-VVQPYUEFSA-M ipratropium bromide Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 LHLMOSXCXGLMMN-VVQPYUEFSA-M 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 229940011051 isopropyl acetate Drugs 0.000 description 1
• GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
• 229960004508 ivacaftor Drugs 0.000 description 1
• PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 108010028309 kalinin Proteins 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 229950002183 lebrikizumab Drugs 0.000 description 1
• 229950007439 lenzilumab Drugs 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
• OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 1
• 108010087711 leukotriene-C4 synthase Proteins 0.000 description 1
• 229950009923 ligelizumab Drugs 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 229940125389 long-acting beta agonist Drugs 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 108010015964 lucinactant Proteins 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• 229950001257 masilukast Drugs 0.000 description 1
• WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
• 229960004655 masitinib Drugs 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000013160 medical therapy Methods 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960005108 mepolizumab Drugs 0.000 description 1
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• FEFIBEHSXLKJGI-UHFFFAOYSA-N methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7h-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate Chemical compound C12=NC(OCCCC)=NC(N)=C2NC(=O)N1CCCN(CC=1C=C(CC(=O)OC)C=CC=1)CCCN1CCOCC1 FEFIBEHSXLKJGI-UHFFFAOYSA-N 0.000 description 1
• 229950010796 methylprednisolone suleptanate Drugs 0.000 description 1
• CDMLLMOLWUKNEK-AOHDELFNSA-M methylprednisolone suleptanate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS([O-])(=O)=O)CC[C@H]21 CDMLLMOLWUKNEK-AOHDELFNSA-M 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 239000003595 mist Substances 0.000 description 1
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 229950007699 mogamulizumab Drugs 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 229960005127 montelukast Drugs 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 239000000234 muscarinic M1 receptor antagonist Substances 0.000 description 1
• 239000003683 muscarinic M2 receptor antagonist Substances 0.000 description 1
• 239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 1
• 239000003149 muscarinic antagonist Substances 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• 108700003805 myo-inositol-1 (or 4)-monophosphatase Proteins 0.000 description 1
• PURKAOJPTOLRMP-ASMGOKTBSA-N n-[2-tert-butyl-4-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-5-hydroxyphenyl]-4-oxo-1h-quinoline-3-carboxamide Chemical compound C1=C(O)C(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-ASMGOKTBSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• NLUPPCTVKHDVIQ-GASCZTMLSA-N n-[5-[4-[5-[[(2r,6s)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1h-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide Chemical compound C1=C(NS(C)(=O)=O)C(OC)=NC=C1C1=CC(C=2OC(CN3C[C@@H](C)O[C@@H](C)C3)=CN=2)=C(C=NN2)C2=C1 NLUPPCTVKHDVIQ-GASCZTMLSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
• 229960004255 nadolol Drugs 0.000 description 1
• 239000000692 natriuretic peptide Substances 0.000 description 1
• 238000002663 nebulization Methods 0.000 description 1
• 229960004398 nedocromil Drugs 0.000 description 1
• RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 235000021313 oleic acid Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 229960004286 olodaterol Drugs 0.000 description 1
• COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 description 1
• 229960004114 olopatadine Drugs 0.000 description 1
• JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
• 229960000470 omalizumab Drugs 0.000 description 1
• 150000002892 organic cations Chemical class 0.000 description 1
• 230000001151 other effect Effects 0.000 description 1
• LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Chemical group 0.000 description 1
• SHZKQBHERIJWAO-AATRIKPKSA-N ozagrel Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 SHZKQBHERIJWAO-AATRIKPKSA-N 0.000 description 1
• 229950003837 ozagrel Drugs 0.000 description 1
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 208000014965 pancolitis Diseases 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 206010033898 parapsoriasis Diseases 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
• 229960001217 perflubron Drugs 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
• 150000003906 phosphoinositides Chemical class 0.000 description 1
• 239000003358 phospholipase A2 inhibitor Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 229960002797 pitavastatin Drugs 0.000 description 1
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229950008515 plecanatide Drugs 0.000 description 1
• 108010018859 plecanatide Proteins 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 230000002206 pro-fibrotic effect Effects 0.000 description 1
• 230000004647 pro-inflammatory pathway Effects 0.000 description 1
• 229960002288 procaterol Drugs 0.000 description 1
• FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
• 206010036784 proctocolitis Diseases 0.000 description 1
• 208000017048 proctosigmoiditis Diseases 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 102000017953 prostanoid receptors Human genes 0.000 description 1
• 108050007059 prostanoid receptors Proteins 0.000 description 1
• 229940121649 protein inhibitor Drugs 0.000 description 1
• 239000012268 protein inhibitor Substances 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000013138 pruning Methods 0.000 description 1
• 230000001823 pruritic effect Effects 0.000 description 1
• 238000010926 purge Methods 0.000 description 1
• 230000001698 pyrogenic effect Effects 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 229950009147 repirinast Drugs 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 229950000150 revefenacin Drugs 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229950007943 risankizumab Drugs 0.000 description 1
• 229950002845 rivipansel Drugs 0.000 description 1
• 229960002586 roflumilast Drugs 0.000 description 1
• MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 229960005328 rupatadine Drugs 0.000 description 1
• WUZYKBABMWJHDL-UHFFFAOYSA-N rupatadine Chemical compound CC1=CN=CC(CN2CCC(CC2)=C2C3=NC=CC=C3CCC3=CC(Cl)=CC=C32)=C1 WUZYKBABMWJHDL-UHFFFAOYSA-N 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 208000001076 sarcopenia Diseases 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229960004540 secukinumab Drugs 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 229940090585 serevent Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 229950007091 setipiprant Drugs 0.000 description 1
• 229950006094 sirukumab Drugs 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 229940126121 sodium channel inhibitor Drugs 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 229950008588 solithromycin Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229960005559 sulforaphane Drugs 0.000 description 1
• 229910052717 sulfur Chemical group 0.000 description 1
• 239000011593 sulfur Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 229950001956 suplatast Drugs 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 229950008041 tadekinig alfa Drugs 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 229950008998 tezepelumab Drugs 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
• 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 description 1
• 230000002992 thymic effect Effects 0.000 description 1
• 229940070124 timapiprant Drugs 0.000 description 1
• 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
• MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 description 1
• 229950004996 tipelukast Drugs 0.000 description 1
• 229960001350 tofacitinib Drugs 0.000 description 1
• UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 229960005342 tranilast Drugs 0.000 description 1
• NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 229950010086 tregalizumab Drugs 0.000 description 1
• 229960002117 triamcinolone acetonide Drugs 0.000 description 1
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
• 229950009163 tridecactide Drugs 0.000 description 1
• ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 1
• 229960000438 udenafil Drugs 0.000 description 1
• 229960004258 umeclidinium Drugs 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• ZYTXTXAMMDTYDQ-DGEXFFLYSA-N vamorolone Chemical compound C([C@H]12)CC3=CC(=O)C=C[C@]3(C)C1=CC[C@@]1(C)[C@H]2C[C@@H](C)[C@]1(O)C(=O)CO ZYTXTXAMMDTYDQ-DGEXFFLYSA-N 0.000 description 1
• 229950011597 vamorolone Drugs 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229960004026 vilanterol Drugs 0.000 description 1
• 229960002282 vilanterol trifenatate Drugs 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 208000005494 xerophthalmia Diseases 0.000 description 1
• 229960004764 zafirlukast Drugs 0.000 description 1
• MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
• 229960005332 zileuton Drugs 0.000 description 1